Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1990 1
1996 3
1997 1
1998 1
1999 1
2002 1
2003 1
2004 2
2005 2
2006 2
2008 1
2009 1
2011 1
2012 1
2013 2
2014 2
2015 2
2017 2
2018 1
2019 1
2020 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Your search for Increased circulating nicotinurate level AND humans[mesh] AND review[publication type] retrieved no results
Antisense Oligonucleotides Targeting Lipoprotein(a).
Langsted A, Nordestgaard BG. Langsted A, et al. Curr Atheroscler Rep. 2019 May 20;21(8):30. doi: 10.1007/s11883-019-0792-8. Curr Atheroscler Rep. 2019. PMID: 31111240 Review.
PURPOSE OF REVIEW: High lipoprotein(a) levels are observationally and causally, from human genetics, associated with increased risk of cardiovascular disease including myocardial infarction and aortic valve stenosis. ...Mipomersen is an antisense oligonucleotide tar …
PURPOSE OF REVIEW: High lipoprotein(a) levels are observationally and causally, from human genetics, associated with increased
Lipid Lowering Therapy and Circulating PCSK9 Concentration.
Nozue T. Nozue T. J Atheroscler Thromb. 2017 Sep 1;24(9):895-907. doi: 10.5551/jat.RV17012. Epub 2017 Aug 14. J Atheroscler Thromb. 2017. PMID: 28804094 Free PMC article. Review.
Next, previous studies evaluating the effects of lipid-modifying pharmacological agents, particularly statins, on circulating PCSK9 concentrations are summarized. Statins decrease hepatic intracellular cholesterol, resulting in increased LDLRs as well as increase
Next, previous studies evaluating the effects of lipid-modifying pharmacological agents, particularly statins, on circulating PCSK9 c …
HDL-Targeting Therapeutics: Past, Present and Future.
Zakiev E, Feng M, Sukhorukov V, Kontush A. Zakiev E, et al. Curr Pharm Des. 2017;23(8):1207-1215. doi: 10.2174/1381612822666161027153140. Curr Pharm Des. 2017. PMID: 27799042 Review.
Large-scale epidemiological studies firmly established the association between low plasma levels of high-density lipoprotein-cholesterol (HDL-C) and elevated risk of cardiovascular disease. ...Over the last decades, wide interest in HDL as an athero- and cardioprotective p …
Large-scale epidemiological studies firmly established the association between low plasma levels of high-density lipoprotein-choleste …
Smoking Cessation Strategies in Pregnancy.
Leung LW, Davies GA. Leung LW, et al. J Obstet Gynaecol Can. 2015 Sep;37(9):791-797. doi: 10.1016/S1701-2163(15)30149-3. J Obstet Gynaecol Can. 2015. PMID: 26605448 Review.
The PubMed, Medline, EMBASE, and Cochrane databases (1990 to 2014) were accessed to identify relevant studies, using the search terms "smoking cessation," "pregnancy," "medicine, behavioural," "nicotine replacement products," "bupropion," and "varenicline." Studies were selected …
The PubMed, Medline, EMBASE, and Cochrane databases (1990 to 2014) were accessed to identify relevant studies, using the search terms "smoki …
Existing and emerging strategies to lower Lipoprotein(a).
Schwartz GG, Ballantyne CM. Schwartz GG, et al. Atherosclerosis. 2022 May;349:110-122. doi: 10.1016/j.atherosclerosis.2022.04.020. Atherosclerosis. 2022. PMID: 35606071 Review.
Some therapies that may reduce cardiovascular risk, such as aspirin, statins, fibrates, and ezetimibe, have little effect on Lp(a) and in some cases may even increase its concentration. Other agents that reduce levels of Lp(a), such as niacin or cholesteryl e …
Some therapies that may reduce cardiovascular risk, such as aspirin, statins, fibrates, and ezetimibe, have little effect on Lp(a) and in so …
Adiponectin and lipoprotein metabolism.
Christou GA, Kiortsis DN. Christou GA, et al. Obes Rev. 2013 Dec;14(12):939-49. doi: 10.1111/obr.12064. Epub 2013 Aug 19. Obes Rev. 2013. PMID: 23957239 Review.
It has also been found to be correlated with various parameters of lipoprotein metabolism, and in particular, it is associated with the metabolism of high-density lipoprotein (HDL) and triglycerides; adiponectin appears to induce an increase in serum HDL, and conversely, H …
It has also been found to be correlated with various parameters of lipoprotein metabolism, and in particular, it is associated with the meta …
Novel LDL-oriented pharmacotherapeutical strategies.
Huang LZ, Zhu HB. Huang LZ, et al. Pharmacol Res. 2012 Apr;65(4):402-10. doi: 10.1016/j.phrs.2012.01.007. Epub 2012 Jan 24. Pharmacol Res. 2012. PMID: 22306845 Review.
Elevated levels of low-density cholesterol (LDL-C) are highly correlated with increased risk of cardiovascular diseases (CVD). ...As for current available LDL-C lowering agents, attentions are mainly focused on statins, niacin, bile acid sequestrants, ezetimi …
Elevated levels of low-density cholesterol (LDL-C) are highly correlated with increased risk of cardiovascular diseases (CVD). …
The complexity of nicotinamide adenine dinucleotide (NAD), hypoxic, and aryl hydrocarbon receptor cell signaling in chronic kidney disease.
Curran CS, Kopp JB. Curran CS, et al. J Transl Med. 2023 Oct 9;21(1):706. doi: 10.1186/s12967-023-04584-8. J Transl Med. 2023. PMID: 37814337 Free PMC article. Review.
Dysregulated enzyme activity in the NAD de novo pathway increases the levels of circulating tryptophan metabolites that activate AHR, resulting in poly-ADP ribose polymerase activation, thrombosis, endothelial dysfunction, and immunosuppression. Therapeutical …
Dysregulated enzyme activity in the NAD de novo pathway increases the levels of circulating tryptophan metabolites that …
Carbohydrate metabolism in cardiovascular disease.
Opie LH, Stubbs WA. Opie LH, et al. Clin Endocrinol Metab. 1976 Nov;5(3):703-29. doi: 10.1016/s0300-595x(76)80047-3. Clin Endocrinol Metab. 1976. PMID: 797485 Review.
Increased provision of glucose by dichloroacetate, and inhibition of FFA metabolism by nicotinic acid analogues decrease the extent of experimental infaraction, while glucose--insulin--potassium and propranolol act both by increasing glucose uptake and decrea
Increased provision of glucose by dichloroacetate, and inhibition of FFA metabolism by nicotinic acid analogues decrease the e
Recent developments in modulating atherogenic lipoproteins.
White CR, Goldberg DI, Anantharamaiah GM. White CR, et al. Curr Opin Lipidol. 2015 Oct;26(5):369-75. doi: 10.1097/MOL.0000000000000216. Curr Opin Lipidol. 2015. PMID: 26270809 Review.
Residual risk may also be present in patients with persistently low HDL-cholesterol despite a reduction in LDL-cholesterol. Recent trials of drugs that increase circulating HDL-cholesterol have also been disappointing. RECENT FINDINGS: Ongoing efforts target the dev …
Residual risk may also be present in patients with persistently low HDL-cholesterol despite a reduction in LDL-cholesterol. Recent trials of …
33 results